A comparison of GOLD 2019 and 2023 recommendations to contemporaneous real-world inhaler treatment patterns for chronic obstructive pulmonary disease management in Singapore

Rayan Alsuwaigh; Anthony Yii; Chee Hong Loh; Xiaomeng Xu; Priti Bahety; Aldo A Navarro Rojas; Dominique Milea; Augustine Tee

doi:10.21037/jtd-22-1769

A comparison of GOLD 2019 and 2023 recommendations to contemporaneous real-world inhaler treatment patterns for chronic obstructive pulmonary disease management in Singapore

J Thorac Dis. 2024 Feb 29;16(2):847-861. doi: 10.21037/jtd-22-1769. Epub 2024 Feb 21.

Authors

Rayan Alsuwaigh¹, Anthony Yii¹, Chee Hong Loh¹, Xiaomeng Xu², Priti Bahety³, Aldo A Navarro Rojas³, Dominique Milea², Augustine Tee¹

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore, Singapore.
² Value Evidence and Outcomes, GSK, Greater China and Intercontinental, Singapore, Singapore.
³ Medical Affairs, GSK, Greater China and Intercontinental, Singapore, Singapore.

Abstract

Background: In 2019 and 2023, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) provided updated strategies for modifying the therapy of patients with chronic obstructive pulmonary disease (COPD) and high exacerbation risk. A key update since the 2019 guidelines recommends considering blood eosinophil count to guide decisions on inhaled corticosteroid (ICS) treatment. To evaluate the potential impact of these updated recommendations, this study aimed to assess how extensively future practice would diverge from contemporaneous prescribing practices at a single center in Singapore, assuming adherence to the 2019 and 2023 GOLD guidelines.

Methods: Retrospective cohort analysis of the Changi General Hospital COPD data warehouse involving patients aged ≥40 years hospitalized for a COPD exacerbation (October 2018-April 2020) receiving long-acting muscarinic antagonist (LAMA), LAMA plus a long-acting beta2-agonist (LABA), or an ICS plus LABA at admission. The proportion of patients eligible for treatment escalations per GOLD 2019 and 2023 recommendations was calculated.

Results: In total, 268 patients were included (mean age 73 years; 91% male). At admission, 19%, 59%, and 22% of patients were receiving LAMA, LAMA + LABA, and ICS + LABA, respectively. Overall, 226 patients would have been eligible for treatment escalation per GOLD 2019 or 2023 recommendations; 31 (13.7%) had treatment escalations consistent with GOLD 2019 guidelines and 34 (15%) received treatment escalations consistent with GOLD 2023 guidelines. A total of 205 patients (76.5%) remained on the same treatment regimen at hospital discharge as they were receiving at admission. Lower measured post-bronchodilator forced expiratory volume in 1 second was associated with treatment escalations that would have been GOLD-concordant (P=0.028), as was increased number of emergency department/hospital visits in the last year (P=0.048).

Conclusions: Compared with real-world clinical practice, a significantly higher proportion of patients may be eligible for treatment escalation under the GOLD 2019 and 2023 eosinophil-directed algorithms.

Keywords: Bronchodilator; Global Initiative for Chronic Obstructive Lung Disease (GOLD); chronic obstructive pulmonary disease (COPD); exacerbation; triple therapy.